[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349685-105":59,"doc-detail-349685-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","multiple-primary-lung-cancer-with-driver-gene-mutations-is-targeted-therapy-always-the-optimal-choice-a-case-report","Multiple Primary Lung Cancer With Driver Gene Mutations - Is Targeted Therapy Always the Optimal Choice? - A Case Report","","Targeted therapy is standard for driver-mutated lung cancer, yet its effectiveness in multiple primary lung cancers (MPLCs) is limited by substantial inter-lesional molecular heterogeneity. The report describes synchronous MPLC with 34 bilateral pulmonary nodules, where an EGFR L858R-mutated adenocarcinoma in the dominant right upper lobe responded to osimertinib while other nodules progressed. Chemoimmunotherapy led to regression, enabling surgical resection; discordant postoperative molecular profiles were found, including a driver-negative lesion, followed by early recurrence and death within 6 months.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/multiple-primary-lung-cancer-with-driver-gene-mutations-is-targeted-therapy-always-the-optimal-choice-a-case-report/349685/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/multiple-primary-lung-cancer-with-driver-gene-mutations-is-targeted-therapy-always-the-optimal-choice-a-case-report/349685.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is targeted therapy less effective for multiple primary lung cancers (MPLCs)?","Question",{"text":112,"@type":113},"Because MPLCs often show significant inter-lesional molecular heterogeneity, so a driver mutation in one lesion may not represent the molecular profile of all lesions.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What was the response of the EGFR-mutated dominant lesion in this case?",{"text":117,"@type":113},"The dominant right upper lobe lesion with an EGFR L858R mutation responded to osimertinib, while other nodules progressed.",{"name":119,"@type":110,"acceptedAnswer":120},"How did treatment decisions change after osimertinib failure?",{"text":121,"@type":113},"Switching to chemoimmunotherapy induced regression of all lesions, allowing definitive surgical resection.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349685,1790380577,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Thoracic Cancer   \n CASE REPORT  OPEN ACCESS   \nMultiple Primary Lung Cancer With Driver Gene Mutations: Is Targeted Therapy Always the Optimal Choice?—A Case Report  \nZi-Rui Ren1  | Lv Wu1 | Chang Lu1 | Fen Wang1,2 | Ying-Long Peng1,3  | Dong-Xuan Cai1  | Li-Bo Tang1,3  |  \nJia-Ting Li1,4 | Zhi Guo1  | Zhi-Hong Chen1 | Yu Deng1 | Lu Sun5 | Xue-Wu Wei1 | Qian-Lin Huang1 | Chong-Rui Xu1  | Qing Zhou1  \n1Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China | 2Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China | 3School of Medicine, South China University of Technology, Guangzhou, China | 4Shantou University Medical College, Shantou, Guangdong, China | 5Department of Pathology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China  \nCorrespondence: Chong-Rui Xu ([xucr001@gmail.com](xucr001@gmail.com)) | Qing Zhou ([gzzhouqing@126.com](gzzhouqing@126.com))  \nReceived: 26 September 2025 | Revised: 8 December 2025 | Accepted: 19 December 2025  \nKeywords: case report | driver gene mutation | molecular heterogeneity | multiple primary lung cancer | targeted therapy  \nABSTRACT  \nTargeted therapy is the standard treatment for driver-mutated lung cancer, but its efficacy in multiple primary lung cancers (MPLCs) remains limited due to significant inter-lesional molecular heterogeneity. We present a case of synchronous MPLC with 34 bilateral pulmonary nodules. The dominant right upper lobe lesion was an EGFR L858R-mutated adenocarcinoma that responded to osimertinib, while other nodules progressed. Switching to chemoimmunotherapy induced regression of all lesions, enabling surgical resection. Postoperative pathological analysis revealed two resected lesions with discordant molecular profiles—one EGFR-mutated and one driver-negative. Despite adjuvant therapy, the patient developed early recurrence as non-small cell lung carcinoma-not otherwise specified with no driver mutation and died within 6 months post-radiotherapy. This case highlights the limitations of single-agent targeted therapy in MPLC, challenges the assumption that driver-negative lesions typically follow an indolent course, and supports early chemotherapy-based systemic combination strategies to address the significant molecular heterogeneity in MPLC.  \n1 | Introduction  \nThe widespread implementation of thin-slice computed tomography (CT) screening has led to increased detection of multiple lung cancers (MLCs), presenting significant diagnostic and therapeutic challenges in clinical practice [1] . MLCs encompass multiple primary lung cancers (MPLCs) and intrapulmonary  \nmetastases (IPM) . Previous studies report that MPLCs constitute 3.72%–5.56% of screen-detected lung malignancies, with superior surgical outcomes compared to IPM [2, 3] . Accurate discrimination between MPLC and IPM is clinically imperative due to their divergent biological behaviors and prognostic implications. Traditional diagnostic criteria have primarily relied on clinical and pathological features, but the latest consensus  \n\n| Zi-Rui Ren and Lv Wu contribute equally to this manuscript. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.\u003Cbr>© 2026 The Author(s) . Thoracic Cancer published by John Wiley & Sons Australia, Ltd. |\n\nThoracic Cancer, 2026; 17:e70215 1 of 5  \n[https://doi.org/10.1111/1759-7714.70215](https://doi.org/10.1111/1759-7714.70215)  \nindicates that diagnostic criteria integrating clinical, imaging, pathological, and molecular evaluations can more accurately dist","cbCaisqy9fgNrC6s","https://ap.wps.com/l/cbCaisqy9fgNrC6s","pdf",3449428,"English","# Introduction\n# Case Presentation","[{\"question\":\"Why is targeted therapy less effective for multiple primary lung cancers (MPLCs)?\",\"answer\":\"Because MPLCs often show significant inter-lesional molecular heterogeneity, so a driver mutation in one lesion may not represent the molecular profile of all lesions.\"},{\"question\":\"What was the response of the EGFR-mutated dominant lesion in this case?\",\"answer\":\"The dominant right upper lobe lesion with an EGFR L858R mutation responded to osimertinib, while other nodules progressed.\"},{\"question\":\"How did treatment decisions change after osimertinib failure?\",\"answer\":\"Switching to chemoimmunotherapy induced regression of all lesions, allowing definitive surgical resection.\"}]","Multiple Primary Lung Cancer With Driver Gene Mutations - Is Targeted Therapy Always the Optimal Choice? - A Case Report | PDF",1790085031,13,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ea1c7c793f3a3782c58dd7cecfb6e1d5.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c40591b10c249fea375c869b47ff2368.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/41cc3a7716bb0160498111d8bee2e8e8.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0fb6b7c46ee6eb997451feff5b8df1d3.webp",980,1287]